PLAU and breast carcinoma: The overexpression of PAI-1, in combination with uPA, is an independent predictive biomarker for disease recurrence and adjuvant chemotherapy response in patients with aggressive breast cancer and has been validated in the clinic on the highest level of evidence [30,45,105].